← All trials
NCT06604611
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chongqing Medical UniversityLead sponsor
- Chongqing Medical UniversityOfficial
- Chongqing Medical UniversitySponsor investigator
- National Natural Science Foundation of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.